February 28, 2018 | Staff Writer

New Biotech in Gaithersburg Bringing 100 Jobs

A new biotech company is opening in Gaithersburg, and is bringing with it 100 new jobs in the next three to five years. Viela Bio, a newly formed spin-out of MedImmune, announced Wednesday it will locate in Gaithersburg and plans to create 100 new jobs within three to five years. The company will focus on […]

Read more

March 4, 2016 | Staff Writer

MedImmune and Johns Hopkins Announce Joint Program to Train Ph.D Students

The Johns Hopkins University and MedImmune announced this week a first-of-its-kind Ph.D. training program between a major university and a biopharmaceutical company in the United States. Known as the Johns Hopkins-MedImmune Scholars Program, this new initiative will build on an ongoing collaboration between MedImmune and Johns Hopkins, and reinforces both partners’ commitment to grow the […]

Read more

October 15, 2015 | Sonya Burke

Five Things to Know Today, Oct. 15, in Montgomery County

Here are your five things to know today, Oct. 15, in Montgomery County: 1. Crews are finishing road repairs at the scene of Tuesday’s water main break at Rockville Pike and Cedar Lane. According to WSSC, all southbound lanes should be open by 8 a.m. today. All northbound lanes are already open. 2. The Maryland […]

Read more

July 19, 2015 | Sonya Burke

Gaithersburg Public Hearing Set for Proposed MedImmune Parking Garage

The Gaithesburg City Council and Planning Commission will hold a joint public hearing at 7:30 p.m. on July 20th to discuss a schematic development plan (SDP) application for construction of a structured parking garage on the MedImmune/Astrazeneca campus. The proposed parking garage would include 1,386 spaces to serve future development on the company’s Gaithersburg campus. […]

Read more

February 11, 2015 | Sonya Burke

MedImmune Alerts Community of Plans to Build Childcare Center

UPDATED MedImmune and AstraZeneca officials are planning to build a child care center adjacent to the company’s corporate campus at One MedImmune Way in Gaithersburg. In an email sent on Feb. 11, the biotech company alerted Quince Orchard Park community residents that a Schematic Development Plan (SDP) application for construction of the child care center […]

Read more

May 12, 2014 | Staff Writer

Members of Maryland Congressional Delegation Send Letter to Pfizer CEO

Six members of the Maryland Congressional delegation have written to Pfizer CEO Ian Read concerning the company’s potential acquisition of AstraZeneca, which employs over 3,000 in Maryland. The letter was led by Congressman John K. Delaney (MD-6) whose district includes the Gaithersburg headquarters of AstraZeneca subsidiary MedImmune. The letter was signed by Senator Barbara A. […]

Read more

May 11, 2014 | Staff Writer

Governors Send Joint Letter of Concern about Potential Acquisition of AstraZeneca

Maryland Governor Martin O’Malley and Deleware Governor Jack Markell sent a letter today to Ian Read, chairman and Chief Executive Officer of Pfizer, Inc., expressing deep concerns about the potential acquisition of AstraZeneca PLC. The letter highlights the potentially significant impact on good, family-sustaining jobs in both Maryland and Delaware, and expresses concern about the […]

Read more

November 17, 2013 | Staff Writer

MedImmune Names Dr. Liu Head of Research

Gaithersburg based MedImmune, the global biologics research and development arm of AstraZeneca, announced Nov. 14 that Yong-Jun Liu, M.D., Ph.D. has been named the company’s new head of research, effective Jan. 6, 2014. Dr. Liu currently serves as vice president and chief scientific officer at the Baylor Research Institute and director of the Baylor Institute […]

Read more

October 30, 2013 | Staff Writer

AstraZeneca Advances MedImmune’s Benralizumab to Phase III

AstraZeneca announced (Oct. 30) the start of the Phase III Windward programme for benralizumab, a potential treatment for severe uncontrolled asthma developed by MedImmune, the company’s global biologics research and development arm. The goal of CALIMA, the first study in the Windward programme, is to determine whether benralizumab reduces the number of exacerbations in patients […]

Read more

October 7, 2013 | Staff Writer

MedImmune Acquires Amplimmune

MedImmune, completed its acquisition of Amplimmune, a privately-held, Gaithersburg based biologics company focused on developing novel therapeutics in cancer immunology. MedImmune acquired 100% of Amplimmune’s shares for an initial consideration of $225 million and deferred consideration of up to $275 million based on reaching established development milestones. Founded in 2007 and headquartered in Gaithersburg, Amplimmune […]

Read more

Engage us on Facebook

Follow us on Twitter